Pay in 4 interest-free payments of $5.62 Learn more
Ships within 48 hours Β· Estimated delivery Aug 7 - Aug 12
SURMOUNT-1, NEJM 2022 57% Lost 20% Body Weight Furthermore, more than half of patients achieved weight loss previously seen only with bariatric surgery
Tirzepatide for the treatment of obesity: rationale and design of the SURMOUNT clinical development program
The medication also has demonstrated heart and kidney health benefits, and researchers are exploring its potential to treat other conditions as well
The smart expansion play is to broaden access to branded, FDA-approved options (injectable and oral GLP-1s), integrate with manufacturer direct channels like LillyDirect and NovoCare, and deepen the services that pure fulfillment can't match: prior authorization and denial-appeal support, employer-benefit syncing to find patients their lowest out-of-pocket cost, nutrition and coaching, and maintenance pathways
Sun CWY, Lau LCM, Cheung JPY, Choi SW
US$ 28.56
US$ 20.91
US$ 20.81
US$ 28.66
US$ 26.21
US$ 29.06
